Cellectis (CLLS) Earnings Date, Estimates & Call Transcripts → AI Hell Will Break Loose [June 30, 2024] … (From Banyan Hill Publishing) (Ad) Free CLLS Stock Alerts $2.67 -0.06 (-2.20%) (As of 06/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 1EstimatedActual EPS (Apr. 29) -$0.64 Missed By -$0.64 Get Cellectis Earnings AlertsEnter your email address below to receive the latest news and earnings results for CLLS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCLLS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CLLS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY Cellectis Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($1.06) EPSNext Year EPS Consensus Estimate: ($0.89) EPSCLLS Earnings Date and InformationCellectis last posted its earnings data on April 29th, 2024. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter. The firm earned $1.99 million during the quarter. Cellectis has generated ($1.29) earnings per share over the last year (($1.29) diluted earnings per share). Earnings for Cellectis are expected to grow in the coming year, from ($1.06) to ($0.89) per share. Cellectis has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off prior year's report dates.Read More Cellectis Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/1/2024(Estimated)------- 4/29/2024Q4 2023-($0.64)($0.64)($0.64)-$1.99 million11/6/2023Q3 2023($0.36)($0.31)+$0.05($0.31)$4.03 million$1.64 million8/3/2023Q2 2023($0.38)($0.14)+$0.24($0.09)$7.80 million$2.00 million5/4/2023Q1 2023($0.30)($0.58)($0.28)($0.58)$9.30 million$3.56 million3/8/2023Q4 2022($0.75)($0.57)+$0.18($0.55)$20.48 million$17.32 million11/3/2022Q3 2022($0.58)($0.63)($0.05)($0.63)$22.45 million$1.92 million Get the Latest News and Ratings for CLLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($0.73)($0.42)+$0.31($0.42)$16.50 million$2.77 million5/12/2022Q1 2022($0.62)($0.70)($0.08)($0.70)$22.85 million$3.83 million3/3/2022Q4 2021($1.05)($0.55)+$0.50($0.55)$12.30 million$13.66 million 12/8/2021Q3($0.80)($0.82)($0.02)--- 11/4/2021Q3 2021($0.82)($0.82)-($0.82)$11.50 million$10.83 million 8/5/2021Q2 2021($0.75)($0.88)($0.13)($0.88)$12.43 million$14.62 million 5/6/2021Q1 2021($0.82)($0.28)+$0.54($0.28)$8.14 million$27.97 million 3/4/2021Q4($1.01)($0.95)+$0.06($0.95)$6.25 million$15.63 million 11/5/2020Q3 2020($0.69)($0.71)($0.02)($0.71)$2.25 million$9.24 million 8/5/2020Q2 2020($0.73)($0.76)($0.03)($0.76)$2.37 million$4.62 million5/6/2020Q1 2020($0.59)$0.47+$1.06$0.47$21.07 million$51.91 million 3/4/2020Q4 2019($0.84)($0.88)($0.04)($0.88)$3.87 million$6.34 million 11/6/2019Q3 2019($0.89)($0.38)+$0.51($0.38)$1.40 million$10.21 million8/6/2019Q2($0.61)($0.79)($0.18)($0.79)$3.45 million$2.93 million Cellectis Earnings - Frequently Asked Questions When is Cellectis's earnings date? Cellectis has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates. Learn more on CLLS's earnings history. How much revenue does Cellectis generate each year? Cellectis (NASDAQ:CLLS) has a recorded annual revenue of $5.15 million. How much profit does Cellectis generate each year? Cellectis (NASDAQ:CLLS) has a recorded net income of -$101.06 million. CLLS has generated -$1.29 earnings per share over the last four quarters. What is Cellectis's EPS forecast for next year? Cellectis's earnings are expected to grow from ($1.06) per share to ($0.89) per share in the next year. More Earnings Resources from MarketBeat Related Companies: iTeos Therapeutics Earnings Date Taysha Gene Therapies Earnings Date Valneva Earnings Date Exscientia Earnings Date Kyverna Therapeutics Earnings Date Adaptive Biotechnologies Earnings Date Cabaletta Bio Earnings Date Alector Earnings Date Lexeo Therapeutics Earnings Date TScan Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:CLLS) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.